Loading
Cancer, Hypoxia, and Metabolism · Journal article
BMC Cancer · September 10, 2026
Raises a question worth testing. It does not answer one.
This is a hypothesis-generating in vitro study that combines machine learning prediction on retrospective patient data with mechanistic experiments in triple-negative breast cancer cell lines. Shikonin is shown to induce necroptosis and apoptosis in hypoxic MDA-MB-231 cells via Parkin-mediated HIF-1α degradation, but the work lacks animal models, clinical trial data, or validation in independent cell systems, and therefore does not constitute evidence of therapeutic benefit.
In vitro mechanistic study with machine learning feature importance analysis on retrospective patient data. MDA-MB-231 triple-negative breast cancer cell line; machine learning training set included data from 1,092 breast cancer patients (retrospective).. Intervention: Shikonin exposure in hypoxic culture conditions; Parkin gene knockdown via siRNA.. Compared with: Normoxic controls; wild-type Parkin versus Parkin-knockdown cells..
Machine learning identified PELI1 and TNFRSF10B as top predictive contributors to necroptosis-hypoxia signature in 1,092 breast cancer patients. Shikonin induced necroptosis and apoptosis in hypoxic MDA-MB-231 TNBC cells, disrupting adaptive pathways including glycolysis and angiogenesis. Parkin mediated HIF-1α ubiquitination and degradation, a process amplified under hypoxic conditions.
No in vivo animal models reported; efficacy and pharmacokinetics in living organisms unknown. No clinical trial data; human safety and tolerability of shikonin not addressed.
This work does not yet provide clinical guidance. While it nominates shikonin as a candidate for TNBC and suggests Parkin and HIF-1α as mechanistic targets, translation to patient benefit requires in vivo efficacy studies and clinical trials.
In vitro mechanistic study using cell lines and machine learning on retrospective data; no clinical trial, no animal efficacy model, and no direct evidence of human benefit. Raises questions about shikonin's potential but does not answer them.
As stated by the source record.
Quoted from the source exactly as published.
This work does not yet provide clinical guidance. While it nominates shikonin as a candidate for TNBC and suggests Parkin and HIF-1α as mechanistic targets, translation to patient benefit requires in vivo efficacy studies and clinical trials.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Triple-negative breast cancer (TNBC) poses significant therapeutic challenges due to a lack of targeted therapies and the frequent development of resistance to conventional solutions. This study delved into programmed cell death (PCD) pathways, particularly apoptosis and necroptosis under hypoxic microenvironments, to meet the demand for novel therapeutic strategies. A machine learning model was trained on a combined dataset of necroptosis-related genes and hypoxia-related risk score (HRRS) genes from 1,092 breast cancer patients. SHAP (SHapley Additive exPlanations) was used to evaluate feature importance within the model. Leveraging shikonin’s established role as a necroptosis inducer, its efficacy in hypoxic TNBC microenvironments was evaluated in MDA-MB-231 cells through cell viability assays, protein expression profiling related to necroptosis, apoptosis analysis, and transcriptomic profiling. Mechanistically, co-immunoprecipitation and ubiquitination assays were performed to investigate Parkin-HIF-1α interactions, while siRNA-mediated Parkin knockdown coupled with CCK-8 assays assessed shikonin cytotoxicity dependence on Parkin. Machine learning identified pellino E3 ubiquitin protein ligase 1 (PELI1) and TNF receptor superfamily member 10b (TNFRSF10B) as top predictive contributors. RNA-sequencing analysis revealed that hypoxic TNBC cells relied on adaptive pathways (e.g., glycolysis, erythropoiesis, angiogenesis), which were disrupted by shikonin via cell death activation. Mechanistically, Parkin mediated HIF-1α ubiquitination and degradation, a process amplified under hypoxia. Our findings demonstrate that shikonin overcomes hypoxia-induced therapeutic resistance through dual induction of necroptosis and apoptosis in TNBC. Mechanistically, Parkin mediates shikonin’s anti-cancer effects by promoting ubiquitination and degradation of HIF-1α, effectively disrupting hypoxic adaptation. These results nominate shikonin as a promising hypoxia-selective agent, and suggest that combinatorial strategies targeting PELI1 and TNFRSF10B pathways may enhance therapeutic efficacy against resistant TNBC.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.